We are pleased to have advised the founders of Atco Pharma on RMBV’s “RNAF III” fund’s acquisition of a 50% stake in the company, marking a significant transaction in Egypt’s pharmaceutical and veterinary sector.

The investment aims to expand ATCO Pharma’s regional footprint, with Dr Ahmed Abo El-naga continuing to lead the company as Chief Executive Officer.

Our team was led by Dr Ahmed Abdelgawad, Senior Partner – Co-Head of M&A and Restructuring, Managing Associates Mariam Choukri and Soha Hussein, assisted by Associates Malak Abda and Maryam Shahien.

Congratulations to Dr Mostafa Abu El-Naga, Chairman and Co-Founder, Eng. Mohammed Abu El-Naga, Vice Chairman and Co-Founder, and Dr Ahmed Abo El-Naga, CEO of ATCO Pharma on this achievement.

We are pleased to have worked alongside Omar Zakaria, Managing Director, Mariam Sherif, Director, and Ahmed Maharem, Investment Banking Associate Vice President of Zilla Capital, Financial Advisors to ATCO Pharma, and Matouk Bassiouny, legal counsel to RMBV.

For more information, check out Africa Investor Review's coverage here:
https://lnkd.in/eY4qpg-N